Prevention & lipidsSecondary analysis
Comparative Cardiovascular Benefits of Bempedoic Acid and Statin Drugs
- Secondary analysis of the CLEAR Outcomes randomised trial
- Cholesterol Treatment Trialists' Collaboration (CTTC) methodology
- HRs normalized per 1 mmol/L low-density lipoprotein cholesterol (LDL-C) difference
Authors' conclusion
Cardiovascular risk reduction with bempedoic acid is similar to that achieved with statins for a given absolute magnitude of LDL-C lowering.
Study context
- Population
- Statin-intolerant patients enrolled in the CLEAR Outcomes trial
- Participants
- 13,970 patients
- Comparison
- Bempedoic acid vs Placebo
- Primary endpoint
- First major vascular event:
- CTTC: CHD death
- Nonfatal MI
- Fatal or nonfatal stroke
- Coronary revascularization
Primary result
As reported in the abstract
First major vascular event
Bempedoic acid vs PlaceboHazard ratio (95% CI)
First major vascular event
0.85(0.77–0.94)
normalized per 1 mmol/L LDL-C reduction; statins in CTTC meta-analysis: rate ratio 0.78
0.75(0.63–0.90)
Further findings
Major coronary events, nonfatal MI, coronary revascularization (normalized)
- Normalized risk reductions similar for bempedoic acid and statins
Original publication
Comparative Cardiovascular Benefits of Bempedoic Acid and Statin Drugs. J Am Coll Cardiol. Published 9 July 2024. doi:10.1016/j.jacc.2024.04.048
Summarised from the published abstract; every number is checked against it